Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Gained about 20% over 21 sessions and surged 17.9% after the latest GSK licensing deal delivered $110 million upfront and up to $1.295 billion in potential payments. Positive Phase III data and recent Chinese approvals add clinical and regulatory support.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Negative Cash Flow ⢠Investment Concentration HCM has strong liquidity and low leverage, but its reported profits rely on non-operating gains amid negative core cash flow, warranting caution until operational performance improves.
Price Behavior
Key Price Behavior Insights: ⢠Strong monthly rally ⢠Breakout above $12.63 ⢠Stretched momentum Support Level: $12.60â$12.65 Resistance Level: $14.09â$14.11 HCM gained 19% over the last month, but with RSI near 75, watch for a pullback unless it decisively breaks $14.09â$14.11; support sits at $12.60â$12.65.
Sentiment & News
Key News Insights: ⢠GSK licensing deal ⢠Savolitinib survival data ⢠Atled China approval Hutchmed gains major momentum from its $1.3B potential GSK deal, positive savolitinib data, and Atled's China approval, strengthening its oncology growth outlook.
AI Summary
HUTCHMED's GSK partnership meaningfully validates its discovery platform and funds global upside, but investors should treat HMPL-A830 as option value and require evidence that savolitinib and newly approved China products can convert into sustainable revenue and positive operating cash flow before chasing the news-driven rerating.
Description
HUTCHMED (China) Limited is a Hong Kongâbased biopharmaceutical company that discovers, develops and commercializes targeted small molecules and immunotherapies primarily for oncology and selected immunological conditions. Its pipeline comprises multiple classes of targeted agents and epigenetic therapies addressing a range of solid tumors and hematologic malignancies, and the company operates through Oncology/Immunology and Other Ventures segments. HUTCHMED maintains collaboration agreements with several global and Chinese biopharma firms and was incorporated in 2000 (name changed from Hutchison China MediTech Limited in 2021).
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 3 | Sep 10 | HCM | HUTCHMED (China) Limited | Gained about 20% over 21 sessions and surged 17.9% after the latest GSK licensing deal delivered $110 million upfront and up to $1.295 billion in potential payments. Positive Phase III data and recent Chinese approvals add clinical and regulatory support. | Active | -0.1% |